Skip to main content
More capital, looser terms seen in biotech sector

More private capital is flowing into the life sciences sector, valuations are up, financing terms have become more startup friendly and the use of tranching is down, according to a report by law firm Cooley LLP. "The supply and demand balance has shifted towards suppliers of innovation (and thus issuers of equity) in the face of robust capital flows," venture capitalist Bruce Booth writes.

Full Story: